758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors
Sharma M, Johnson M, Puzanov I, Sznol M, Mckean M, Gainor J, Spira A, Henick B, Tolcher A, Chen C, El-Khoueiry A, Broderick J, Peng L, Che J, Cao L, Wilson D, Lathers D, Horak C, Feltquate D, Luke J. 758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors. 2024, a862-a862. DOI: 10.1136/jitc-2024-sitc2024.0758.Peer-Reviewed Original ResearchPhase 1/2 trialSolid tumors